IRON Disc Medicine Corp: Bathi resik saben siji saham sajrone rolas wulan pungkasan

Logo perusahaan publik Disc Medicine Inc (IRON)

Risks for Disc Medicine, Inc. (IRON) stem from a narrow development pipeline, where failures in blood research threaten a collapse in share prices. Meanwhile, laboratories operate strictly according to protocol, ensuring capacity readiness for synthesis. Growth prospects are driven by the success of bitopertin and DISC-0974, as well as interest from major pharma behemoths. The 12-month YoY change in net income per share on this GURU.Markets chart is -18.00, reflecting the EPS dynamics.

Disc Medicine Inc (IRON): Bathi resik saben saham (EPS TTM) saka 11.02.2024 nganti 18.11.2026

discmedicine.com - rincian analitis lan metrik utama (IRON)

- rega saham lan prakiraan rega para ahli:
Analisis wiwitan perusahaan:IRON (Disc Medicine)
Produk dadi Disc Medicine, Inc.

Year-over-year (TTM) EPS growth measures the dynamics of net income per share over twelve months, allowing for an assessment of actual capitalization efficiency and business growth momentum. For Disc Medicine, Inc. (IRON), the EPS YoY TTM shift reflects the extent to which AI-driven drug synthesis automation converts into financial results against the backdrop of clinical trial expenditures.